Real-World Efficacy of Intravesical Gemcitabine for BCG-Unresponsive Non–muscle-Invasive Bladder Cancer
- Document Type
- Publications · Journal Article
- Registered DB
- KCISCIEScopus
- Journal Ranking
- JCR Q2Scopus Q1KCI Q1
- Journal
- Cancer Research and Treatment58(2) · pp.591 · 2026
- Citation
- Web of Science 1Scopus 1KCI 0
- FWCI (Scopus)
- 1.83
- JCR IF
- JCR 2024 3.8
- ISSN
- 1598-2998
Authors
- Lee, Hye WonFirst authorSungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Urol, Seoul, South Korea
- Jung, Eui HyunNatl Canc Ctr, Ctr Urol Canc, Dept Urol, 323 Ilsan Ro, Goyang 10408, South Korea
- Kim, Kyung HwanPusan Natl Univ, Pusan Natl Univ Hosp, Dept Urol, Coll Med, Busan, South Korea
- Ha, Hong-kooPusan Natl Univ, Pusan Natl Univ Hosp, Dept Urol, Coll Med, Busan, South Korea
- Oh, Jong JinSeoul Natl Univ, Bundang Hosp, Dept Urol, Coll Med, Seongnam, South Korea
- Kang, Seok HoKorea Univ, Coll Med, Dept Urol, Anam Hosp, Seoul, South Korea
- Jeong, Seung-hwanSeoul Natl Univ, Seoul Natl Univ Hosp, Dept Urol, Coll Med, Seoul, South Korea
- Yuk, Hyeong DongSeoul Natl Univ, Seoul Natl Univ Hosp, Dept Urol, Coll Med, Seoul, South Korea
- Heo, Ji EunYonsei Univ, Urol Sci Inst, Dept Urol, Coll Med, Seoul, South Korea
- Ham, Won SikYonsei Univ, Urol Sci Inst, Dept Urol, Coll Med, Seoul, South Korea
- Hwang, Eu ChangChonnam Natl Univ, Hwasun Hosp, Dept Urol, Med Sch, Hwasun, South Korea
- Il Jung, SeungChonnam Natl Univ, Hwasun Hosp, Dept Urol, Med Sch, Hwasun, South Korea
- Song, WanSungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Urol, Seoul, South Korea
- Lim, BumjinUniv Ulsan, Coll Med, Asan Med Ctr, Dept Urol, Seoul, South Korea
- Hong, BumsikUniv Ulsan, Coll Med, Asan Med Ctr, Dept Urol, Seoul, South Korea
- Jeong, Byung ChangSungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Urol, Seoul, South Korea
- Seo, Ho KyungCorresponding authorNatl Canc Ctr, Ctr Urol Canc, Dept Urol, 323 Ilsan Ro, Goyang 10408, South Korea
Abstract
PurposeThis study aimed to report the real-world outcomes of intravesical gemcitabine for bacillus Calmette–Guérin (BCG)–unresponsive, high-risk, non–muscle-invasive bladder cancer (HR-NMIBC) in Korean patients who were unable or unwilling to undergo radical cystectomy (RC).Materials and MethodsThis retrospective study included 131 patients (median age, 69 years; 88.5% men) treated with intravesical gemcitabine for BCG-unresponsive HR-NMIBC at nine centers between May 2019 and April 2022. The primary endpoint was 1-year recurrence-free survival (RFS). The secondary endpoints included factors influencing RFS, progression-free survival (PFS), cystectomy- free survival, cancer-specific survival (CSS), overall survival (OS), and safety. Survival analysis was performed using the Kaplan-Meier method, and risk factors for recurrence were assessed using Cox regression models.ResultsPatients were followed up for a median duration of 25 months, with carcinoma in situ (CIS) in 41.9% of the patients. The 1-year and 2-year RFS rates were 68% and 42%, while the 1-year and 2-year PFS rates were 87% and 77%, respectively. No significant factors influencing RFS were identified. Seventeen patients underwent RC during a median follow-up of 16 months, with the condition in three patients progressing to muscle-invasive disease on final pathological analysis. The 2-year CSS and OS rates were 98% and 97%, respectively. Intravesical gemcitabine was well-tolerated, with only seven patients (5.3%) unable to complete the full induction course.ConclusionOur research highlights the potential of intravesical gemcitabine as a viable bladder-sparing treatment option for BCG-unresponsive HR-NMIBC, providing real-world evidence on its safety, efficacy, and tolerability.
Keywords
TherapeuticsNon-muscle invasive bladder neoplasmsBacillus Calmette–GuérinFailureOrganization and administrationIntravesical administrationGemcitabineOrgan preservation
Identifiers
- Scopus EID
- 2-s2.0-105035841246
- WoS UID
- 001743756600021
- KCI
- ART003325921



Login
Back to Publication list